Erasca, Inc. Common Stock
$14.77
-$0.57 (-3.72%)
$14.51Day Range$15.47
Key Statistics
Market Cap
$5.37B
Shares Outstanding
349.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 16, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$15.41
Day High
$15.47
Day Low
$14.51
Volume
8.69M
VWAP
$14.84
Prev Close
$15.34
Transactions
--
Acc. Volume
--
About Erasca, Inc. Common Stock
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
PHARMACEUTICAL PREPARATIONSSIC 2834103 employees3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121(858) 465-6511IPO Jul 16, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001761918
- Composite FIGI
- BBG00MTSR883
- Share Class FIGI
- BBG00MTSR892
- Ticker Root
- ERAS
- SIC Code
- 2834
About Erasca, Inc. Common Stock (ERAS) Stock
Erasca, Inc. Common Stock (ERAS) closed the 2026-09-18 session at $14.77, down 3.72% versus the previous close (-0.57). The stock opened at $15.41 and traded between $14.51 and $15.47 during that session. Session trading volume was 8.7M shares. The volume-weighted average price (VWAP) is $14.84.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Erasca, Inc. Common Stock has a market capitalization of $5.37 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ERAS is listed on the XNAS exchange. The company employs approximately 103 people. Erasca, Inc. Common Stock is headquartered in SAN DIEGO, CA. The recorded listing date is 2021-07-16.
On this page you can find market ERAS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.